MD, PhD, FASN, FAST, Professor Haraldsson has served for 15 years as Chair of nephrology at the University of Gothenburg, Sweden, and as senior consultant at the nephrology clinic at Sahlgrenska University hospital, Gothenburg. Most recently, he initiated and lead high-profile global drug development projects in nephrology, transplantation, and rheumatology at Novartis, Switzerland. Read more about Börje Haraldsson here.
MBA, PhD in Clinical Nephrology focused Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway.
PhD in Clinical Immunology Karolinska Institute, PMP. Susanna Dahlgren has a long experience in drug development from various positions in the pharmaceutical industry including Astrazeneca, ALK, Polypeptide, Aqilion and SDS Life Science, focusing on project leadership from early drug discovery to clinical development, medical affairs and scientific marketing. Read more about Susanna Dahlgren here.
MD, PhD in clinical pharmacology. Associate Professor Hanjing Xie is triple board certified in Clinical Oncology, Internal Medicine and Hematology and has 31 years of accumulated experience in clinical, research and drug development. Before expanding her horizons in the pharma industry, Hanjing Xie served as senior consultant at Karolinska University Hospital. In the life science sector, Hanjing Xie has taken various senior leading positions at both big pharma and small biotech companies including Bayer, Oncopeptides, Idogen, Kancera, and NeoGap.
MSc Pharm from Uppsala University. Åsa Holmgren has over 30 years of experience in Global Strategic Regulatory Affairs and Drug Development in pharmaceutical companies. She has held leadership positions and led regulatory strategies at Medivir AB, Orexo AB, AstraZeneca R&D, Pharmacia & Upjohn R&D, and Roche AB. Read more about Åsa Holmgren here.